Residency · Maywood, IL
Sponsored by Loyola University Medical Center
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
The New England journal of medicine · 2023 · 703 citations · Sudarshan Sharma
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022 · 358 citations · Charles Anderson
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
The Lancet. Oncology · 2021 · 348 citations · Charles Anderson
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · 336 citations · Charles Anderson, Sudarshan Sharma
Ovarian cancer mutational processes drive site-specific immune evasion.
Nature · 2022 · 272 citations · Vance Broach
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025.
Journal of the National Comprehensive Cancer Network : JNCCN · 2025 · 55 citations · Karina Nieto
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.
Annals of oncology : official journal of the European Society for Medical Oncology · 2024 · 109 citations · Sudarshan Sharma
Sense of Belonging Among Medical Students, Residents, and Fellows: Associations With Burnout, Recruitment Retention, and Learning Environment.
Academic medicine : journal of the Association of American Medical Colleges · 2025 · 31 citations · Shannon Laughlin-Tommaso